Invasive fungal infection after heart transplantation: A 7-year, single-center experience

Transpl Infect Dis. 2017 Feb;19(1). doi: 10.1111/tid.12650. Epub 2017 Jan 27.

Abstract

Background: Invasive fungal infections (IFIs) are an infrequent but major complication of heart transplantation (HT). We sought to describe the epidemiology at our institution.

Methods: A prospective cohort study of 159 heart transplant recipients was performed from June 2005 to December 2012. IFIs were defined by European Organization for Research and Treatment of Cancer/Mycoses Study Group criteria.

Results: By univariate analysis, Hispanic ethnicity was associated with IFI (P=.01, odds ratio [OR] 7.0, 95% confidence interval [CI] 1.7-27.9). Subsequently, a multivariate logistic regression was performed adjusting for Hispanic ethnicity, age, and gender. Seventeen IFIs were identified, occurring at a median 110 days post HT (interquartile range: 32-411 days). Five IFIs (29% of IFIs and 3.1% of all HT) occurred during the HT hospitalization, with 13 IFIs during the first year (incidence 8.2%).

Conclusions: The cumulative incidence was 10.7%. IFIs were associated with pre- and post-HT vancomycin-resistant Enterococcus colonization and/or infection, post-HT renal replacement therapy, anti-thymocyte globulin induction, and antibody-mediated rejection. There were no associations with diabetes mellitus, desensitization, 2R/3R cellular rejection, treatments for rejection, re-operation, neutropenia, or cytomegalovirus infection. IFIs were associated with death (P=.02, OR 3.9, 95% CI 1.3-12.1) and 1-year mortality (P<.001, OR 9.0, 95% CI 2.3-35.7), but not 3-year mortality. Associations with Hispanic ethnicity must be validated. Optimal strategies for risk reduction and prophylaxis remain undefined.

Keywords: Aspergillosis; candidiasis; heart transplantation; invasive fungal infection.

Publication types

  • Observational Study

MeSH terms

  • Antilymphocyte Serum / administration & dosage
  • Antilymphocyte Serum / adverse effects*
  • Antilymphocyte Serum / therapeutic use
  • Female
  • Graft Rejection / complications*
  • Graft Rejection / immunology
  • Gram-Positive Bacterial Infections / complications*
  • Gram-Positive Bacterial Infections / microbiology
  • Heart Transplantation / adverse effects*
  • Humans
  • Immunocompromised Host
  • Immunosuppression Therapy / adverse effects
  • Immunosuppression Therapy / methods
  • Immunosuppressive Agents / administration & dosage
  • Immunosuppressive Agents / adverse effects*
  • Immunosuppressive Agents / therapeutic use
  • Incidence
  • Invasive Fungal Infections / complications*
  • Invasive Fungal Infections / epidemiology*
  • Male
  • Middle Aged
  • Odds Ratio
  • Prospective Studies
  • Renal Dialysis / adverse effects
  • Risk Factors
  • Vancomycin-Resistant Enterococci / isolation & purification*

Substances

  • Antilymphocyte Serum
  • Immunosuppressive Agents